Beisol Pharma Lubbeek: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Beisol Pharma Lubbeek
Largest movements
- Intangible fixed assets -€16,344
down €16,344 (-15.0%), from €108,964 to €92,620
- Receivables within one year +€3,392
up €3,392 (+854%), from €397 to €3,789
- Trade debts -€10,500
no longer reported in 2026 (was €10,500)
- Other debts -€5,753
down €5,753 (-6.4%), from €89,930 to €84,177
- Reserves +€3,300
up €3,300 (+83.0%), from €3,975 to €7,275
of which Distributable reserves: +€3,135
- Gross operating margin +€2,075
up €2,075 (+11.1%), from €18,646 to €20,721
- Purchases and services -€2,075
down €2,075 (-18.3%), from €11,354 to €9,279
- Taxes -€1,014
no longer reported in 2026 (was €1,014)
- Other operating charges +€634
up €634 (+164%), from €387 to €1,021
From the 2025 result to the 2026 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2025 and 2026 balance sheets and the 2026 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2025 | 2026 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €109,405 | €96,452 | -€12,953 | -11.8% |
| Fixed assets | 21/28 | €108,964 | €92,620 | -€16,344 | -15.0% |
| Intangible fixed assets | 21 | €108,964 | €92,620 | -€16,344 | -15.0% |
| Current assets | 29/58 | €441 | €3,832 | +€3,391 | +769% |
| Amounts receivable within one year | 40/41 | €397 | €3,789 | +€3,392 | +854% |
| Other amounts receivable | 41 | €397 | €3,789 | +€3,392 | +854% |
| Cash at bank and in hand | 54/58 | €44 | €43 | -€1 | -2.3% |
| Total equity and liabilities | 10/49 | €109,405 | €96,452 | -€12,953 | -11.8% |
| Equity | 10/15 | €8,975 | €12,275 | +€3,300 | +36.8% |
| Contributions | 10/11 | €5,000 | €5,000 | = | 0.0% |
| Capital | 10 | €5,000 | €5,000 | = | 0.0% |
| Issued capital | 100 | €5,000 | €5,000 | = | 0.0% |
| Reserves | 13 | €3,975 | €7,275 | +€3,300 | +83.0% |
| Non-distributable reserves | 130/1 | €199 | €364 | +€165 | +82.9% |
| Legal reserve | 130 | €199 | €364 | +€165 | +82.9% |
| Distributable reserves | 133 | €3,776 | €6,911 | +€3,135 | +83.0% |
| Amounts payable | 17/49 | €100,430 | €84,177 | -€16,253 | -16.2% |
| Amounts payable within one year | 42/48 | €100,430 | €84,177 | -€16,253 | -16.2% |
| Trade debts | 44 | €10,500 | - | -€10,500 | |
| Suppliers | 440/4 | €10,500 | - | -€10,500 | |
| Other amounts payable | 47/48 | €89,930 | €84,177 | -€5,753 | -6.4% |
| Turnover | 70 | €30,000 | €30,000 | = | 0.0% |
| Goods, raw materials, services and sundry goods | 60/61 | €11,354 | €9,279 | -€2,075 | -18.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €16,345 | €16,345 | = | 0.0% |
| Other operating charges | 640/8 | €387 | €1,021 | +€634 | +164% |
| Gross operating margin | 9900 | €18,646 | €20,721 | +€2,075 | +11.1% |
| Operating profit (loss) | 9901 | €1,914 | €3,355 | +€1,441 | +75.3% |
| Financial charges | 65/66B | €275 | €55 | -€220 | -80.0% |
| Recurring financial charges | 65 | €275 | €55 | -€220 | -80.0% |
| Profit (loss) for the period before taxes | 9903 | €1,639 | €3,300 | +€1,661 | +101% |
| Income taxes | 67/77 | €1,014 | - | -€1,014 | |
| Profit (loss) for the period | 9904 | €625 | €3,300 | +€2,675 | +428% |
| Profit (loss) for the period to be appropriated | 9905 | €625 | €3,300 | +€2,675 | +428% |
Source: filed annual accounts (NBB), financial years ended 31 March 2025 and 31 March 2026. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 23 October 2026 via checked.be.